@article{9bd5fc45-6d07-458b-aa9a-6bd160c64caa,
  abstract     = {{<p>Advances in biomarker technology, digital cognitive assessments, and amyloid-targeting therapies have redefined the opportunities for accurate and early diagnosis and care of Alzheimer's disease (AD). These advances also create new possibilities for intervention before the onset of cognitive impairment. This paradigm shift has increased the focus on Stages 1 and 2 of AD, in which individuals are cognitively unimpaired but exhibit biological evidence of disease. While early identification of AD offers an opportunity to intervene early to delay progression and preserve quality of life, it also presents complex challenges related to communicating diagnostic results to patients and their families, contextualizing the cost effectiveness of early diagnosis and treatment, and implementation of and equitable access to treatments. Recent, successfully enrolled, preclinical AD trials highlight the complex strategies required to identify asymptomatic, biomarker-positive individuals on a large scale, and demonstrate critical knowledge gaps in inclusion, follow-up, and long-term outcome measurement. The Spring 2025 Alzheimer's Association Research Roundtable (AARR) meeting brought together academics, clinicians, industry, and regulatory leaders to exchange perspectives on current challenges, key learnings, and potential strategies for identifying and treating individuals in very early stages of AD, effectively and safely. This paper presents key takeaways from the Spring 2025 AARR meeting. Highlights: New criteria for Alzheimer's disease (AD) enable early identification of AD pathology. Blood tests and digital cognitive assessment tools may facilitate early and personalized care. Plasma biomarkers may be scalable in clinical settings but need confirmation or follow-up assessments in those individuals with equivocal results. Early therapy shows best results in people with lower initial amyloid and tau burden.</p>}},
  author       = {{Schindler, Suzanne E. and Hansson, Oskar and Algeciras-Schimnich, Alicia and Arias, Jalayne J. and Beasley, Brent and Farrar, Gill and Fowler, Nicole R. and Hartz, Sarah M. and Jack, Clifford R. and Jönsson, Linus and Joyce, Geoffrey and Lansdall, Claire J. and Maruff, Paul and Mattsson-Carlgren, Niklas and Mummery, Catherine Jane and Murphy, Jennifer and Okhravi, Hamid and Petersen, Ronald C. and Raman, Rema and Randolph, Christopher and Sass, Marie Reeberg and Reiman, Eric M. and Salvadó, Gemma and Schöll, Michael and Siemers, Eric and Sperling, Reisa A. and Thornton-Wells, Tricia and Tortelli, Rosanna and Tosun, Duygu and Vandevrede, Lawren and Villain, Nicolas and Weninger, Stacie and Wessels, Alette M. and Zhou, Jin and Carrillo, Maria C. and Weber, Christopher J.}},
  issn         = {{2352-8737}},
  keywords     = {{Alzheimer's disease; amyloid; biomarkers; early diagnosis; early intervention; Research Roundtable}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{1}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Alzheimer's and Dementia: Translational Research and Clinical Interventions}},
  title        = {{Alzheimer's disease Stage 1 and 2 : Biology, diagnostics, and treatment}},
  url          = {{http://dx.doi.org/10.1002/trc2.70216}},
  doi          = {{10.1002/trc2.70216}},
  volume       = {{12}},
  year         = {{2026}},
}